Publication | Closed Access

Reductions in 30-day readmission, mortality, and costs with inpatient–to–community pharmacist follow-up

Health PolicyHealth EconomicsPharmaceutical PracticePatient SafetyClinical PharmacyOutcomes ResearchPharmaceutical Care30-Day ReadmissionPharmacoeconomicsPharmacotherapyPublic HealthMedicineHealth Services ResearchPharmacoepidemiologyInpatient–to–community Pharmacist Follow-up